Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Pancreatic Cells Derived from Human Embryonic Stem Cells Cure Diabetes in Rodent Models

By BiotechDaily International staff writers
Posted on 12 Jul 2012
Print article
Commercially available human embryonic stem cells (hESCs) have been induced to differentiate into fully functional pancreatic beta cells that were capable of restoring insulin production and regularizing glucose metabolism in two different rodent diabetes models.

Investigators at the University of British Columbia (Vancouver, Canada) and their colleagues at the biotechnology firm BetaLogics (Raritan, NJ, USA) developed a protocol to differentiate commercially available human embryonic stem cells (hESCs) in vitro into a highly enriched PDX1+ pancreatic progenitor cell population. These cells progressed in vivo into mature pancreatic endocrine cells.

Immature pancreatic precursor cells were transplanted into immunodeficient mice with streptozotocin-induced diabetes. Glycemia was initially controlled with exogenous insulin; however, as insulin levels derived from the grafted stem cells increased over time, the mice were weaned from the insulin. Glucose metabolism was eventually regulated by meal and glucose challenges. Similar differentiation of pancreatic precursor cells was observed after transplant into immunodeficient rats.

Additional details published in the June 27, 2012, online edition of the journal Diabetes revealed that throughout the in vivo maturation period hESC-derived endocrine cells exhibited gene and protein expression profiles that were remarkably similar to that of cells in the developing human fetal pancreas.

"We are very excited by these findings, but additional research is needed before this approach can be tested clinically in humans," said senior author Dr. Timothy Kieffer, professor of cellular and physiological sciences at the University of British Columbia. "The studies were performed in diabetic mice that lacked a properly functioning immune system that would otherwise have rejected the cells. We now need to identify a suitable way of protecting the cells from immune attack so that the transplant can ultimately be performed in the absence of any immunosuppression."

Related Links:
University of British Columbia
BetaLogics


Print article

Channels

Drug Discovery

view channel
Image: Schematic diagram of dendrimer structure (Photo courtesy of the University of California, Irvine).

Dendrimer-Transported MicroRNA Shown Effective in Treating Mice with Late-Stage Liver Cancer

Cancer researchers have used nanocarriers called dendrimers to transport a specific tumor growth-inhibiting microRNA (miRNA) to the livers of mice with late-stage liver cancer. MicroRNAs are a class... Read more

Business

view channel

Purchase Agreement to Boost Ebola Vaccine Development

A deal to help boost development of a vaccine to protect against Ebolavirus infection was finalized at the recent Davos Conference in Switzerland. Gavi (Geneva, Switzerland), the global alliance for vaccines and immunizations, announced that it would spend five million USD to purchase the Ebola vaccine under development... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.